MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, HRTX made $38,213K in revenue. -$17,494K in net income. Net profit margin of -45.78%.

Income Overview

Revenue
$38,213K
Net Income
-$17,494K
Net Profit Margin
-45.78%
EPS
-$0.1
Unit: Thousand (K) dollars
Revenue Breakdown
    • CINVANTI
    • ZYNRELEF
    • Aponvie
    • SUSTOL

Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-12-31
Net product sales
38,213 37,200 38,903 45,342*
Cost of product sales
11,914 9,857 8,457 10,274*
Gross profit
26,299 27,343 30,446 35,068*
Research and development
3,470 2,934 2,279 3,288*
General and administrative
13,980 14,471 12,702 16,278*
Sales and marketing
12,942 11,575 12,311 14,169*
Total operating expenses
30,392 28,980 27,292 33,735*
Gain from operations
-4,093 -1,637 3,154 1,333*
Loss on debt extinguishment
-11,339 ---
Other expense, net
-2,063 -744 -519 108*
Interest expense
---1,508*
Interest income
---888*
Total other (expense) income, net
----513*
Net gain
-17,495 -2,381 2,635 820
Unrealized gain (loss) on short-term investments
1 -2 -12 -
Comprehensive gain
-17,494 -2,383 2,623 820
Basic EPS
-0.1 -0.02 0.02 0.005
Diluted EPS
-0.1 -0.02 0.01 0.005
Basic Average Shares
170,348,000 154,020,000 153,490,000 152,068,000
Diluted Average Shares
170,348,000 154,020,000 196,921,000 152,068,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive gain-$17,494K (-264.46%↓ Y/Y)Unrealized gain (loss) onshort-term investments$1K (-97.92%↓ Y/Y)CINVANTI$23,955K ZYNRELEF$9,313K Aponvie$3,034K SUSTOL$1,911K Net gain-$17,495K (-260.87%↓ Y/Y)Net product sales$38,213K (16.47%↑ Y/Y)Loss on debtextinguishment-$11,339K Gain from operations-$4,093K (8.19%↑ Y/Y)Other expense, net-$2,063K (-428.97%↓ Y/Y)Gross profit$26,299K (12.62%↑ Y/Y)Cost of product sales$11,914K (25.97%↑ Y/Y)Total operatingexpenses$30,392K (9.28%↑ Y/Y)General andadministrative$13,980K (12.99%↑ Y/Y)Sales and marketing$12,942K (17.95%↑ Y/Y)Research and development$3,470K (-22.28%↓ Y/Y)

HERON THERAPEUTICS, INC. DE (HRTX)

HERON THERAPEUTICS, INC. DE (HRTX)